Overview
Fadogia agrestis is a Nigerian shrub that has gained considerable popularity in fitness and athletic communities as a natural testosterone-boosting supplement. The plant's stem extract is marketed primarily to athletes and bodybuilders seeking to enhance luteinizing hormone (LH)-driven testosterone production, often used in combination with other supplements like Tongkat Ali. Despite its growing commercial availability and use, Fadogia agrestis remains poorly understood from a human safety and efficacy perspective. The existing evidence base is severely limited, with virtually all research derived from rodent studies rather than clinical human trials.
The supplement industry promotes Fadogia agrestis for multiple purposes including testosterone support, libido enhancement, and potential improvements in physical performance. However, the scientific evidence supporting these claims varies dramatically by health outcome, with most purported benefits lacking any human clinical data whatsoever. Understanding what the research actually shows—and, critically, what it does not show—is essential for anyone considering this supplement.
How It Works: Mechanism of Action
Fadogia agrestis is theorized to work through multiple physiological pathways, though most mechanisms remain incompletely understood in humans.
Primary Testosterone Production Pathway
The primary proposed mechanism involves stimulation of luteinizing hormone (LH) release from the anterior pituitary gland. When LH is elevated, it signals Leydig cells in the testes to increase testosterone biosynthesis. The active compounds in Fadogia agrestis extract—particularly saponins and alkaloids—are believed to interact with gonadotropin-releasing hormone (GnRH) pathways, potentially triggering this LH cascade.
Additionally, some evidence suggests the plant extract may directly stimulate steroidogenic enzyme activity at the testicular level, independent of the LH signal. This dual-pathway theory remains largely speculative in humans, as it has only been demonstrated in rodent models.
Secondary Mechanisms: Aphrodisiac and Antioxidant Activity
Beyond testosterone elevation, Fadogia agrestis contains compounds with proposed aphrodisiac properties that may act on dopaminergic and androgen-sensitive neural pathways. Rat studies have also documented increased antioxidant markers in penile and testicular tissues, including elevated catalase, superoxide dismutase (SOD), glutathione (GSH), and glutathione S-transferase (GST) activity. However, it remains unclear whether these antioxidant effects translate to meaningful health benefits in humans or represent a compensatory response to cellular stress.
Evidence by Health Goal
Muscle Growth: Tier 1 (No Evidence)
Evidence Rating: Tier 1 — No human or animal efficacy data.
Despite widespread use among bodybuilders, Fadogia agrestis has not been studied for muscle growth in humans or animals. The four available scientific studies examine sexual function, erectile dysfunction, testicular function, or organ toxicity—none of which directly assess skeletal muscle development or hypertrophy.
The only relevant finding is a dose-dependent increase in serum testosterone in male rats at doses of 18, 50, and 100 mg/kg body weight. While elevated testosterone is theoretically associated with muscle protein synthesis, this connection has not been demonstrated with Fadogia agrestis supplementation in any study population.
Bottom line: Manufacturers market this supplement for muscle growth, but zero scientific evidence supports its efficacy for this purpose.
Testosterone & Hormonal Balance: Tier 2 (Limited Animal Evidence)
Evidence Rating: Tier 2 — Animal studies only; no human trials.
Fadogia agrestis demonstrates testosterone-elevating effects in male rats, though only animal models have been studied. In research examining male rats receiving aqueous plant extract at doses of 18, 50, and 100 mg/kg body weight over 5 days, serum testosterone concentrations increased significantly in a dose-dependent manner (p<0.05). This is the strongest evidence the supplement possesses, yet it remains confined to rodent research.
Crucially, no human clinical trials exist demonstrating whether oral supplementation with Fadogia agrestis elevates testosterone in men. The doses used in rat studies were also normalized to body weight—meaning a 100 kg human would require substantially higher absolute doses to achieve equivalent exposure, a translation that may not be valid between species.
Sexual Health & Erectile Function: Tier 2 (Limited Animal Evidence)
Evidence Rating: Tier 2 — Animal studies only; no human efficacy data.
Fadogia agrestis shows promise for sexual health markers exclusively in rodent models. In male rats receiving extract at 18-100 mg/kg, the supplement increased mount frequency and intromission frequency while reducing latency periods (p<0.05). These measures are used as indicators of sexual motivation and function in animal research.
In separate rat studies, Fadogia agrestis extract increased penile and testicular nitric oxide (NO) and cyclic guanosine monophosphate (cGMP)—signaling molecules critical for erectile function—while reducing phosphodiesterase type 5 (PDE5) and arginase. The magnitude of these changes was reported as comparable to sildenafil (Viagra) in paroxetine-treated rats, though this comparison is somewhat misleading since paroxetine is a selective serotonin reuptake inhibitor used to treat depression, not erectile dysfunction in the animal model.
Critical gap: Zero human evidence supports any benefit for erectile dysfunction or sexual performance. The animal data is suggestive but insufficient to recommend this supplement for sexual health purposes in people.
Inflammation & Anti-Inflammatory Effects: Tier 1 (No Evidence)
Evidence Rating: Tier 1 — No human or animal efficacy studies.
Despite anecdotal claims of anti-inflammatory benefits, Fadogia agrestis has not been studied for its ability to reduce inflammation in any human or animal model. The only available research is a chemical analysis study documenting the presence of 11 measurable phenolic compounds via ultra-high-performance liquid chromatography (UHPLC-PDA-MS), with detection limits of 0.025–0.1 µg/mL.
While phenolic compounds are theoretically associated with antioxidant and anti-inflammatory properties in other botanical supplements, Fadogia agrestis has never been tested for actual inflammatory outcomes. A survey of 17 commercial supplements claiming to contain Fadogia agrestis found phenolic compound ranges of 0.3–2.7 mg/day, but no inflammatory markers were measured in any participant.
Bottom line: The presence of potentially bioactive compounds does not demonstrate efficacy. This remains an untested claim.
Mood, Stress & Mental Health: Tier 1 (No Evidence)
Evidence Rating: Tier 1 — No human evidence; irrelevant animal data.
No human studies exist examining Fadogia agrestis for mood, stress, anxiety, or any psychiatric outcome. The two available animal studies focusing on reproductive and testicular function provide no relevant data for mental health assessment.
Marketing claims regarding mood enhancement or stress reduction are entirely unsupported by scientific literature.
Immune Support: Tier 1 (In Vitro Only, No Human or Animal Data)
Evidence Rating: Tier 1 — In vitro screening only; no human or animal efficacy studies.
A single ethnobotanical survey documented that Fadogia agrestis alkaloid extract showed in vitro antiplasmodial activity against Plasmodium falciparum (a malaria parasite), with an IC50 (half-maximal inhibitory concentration) of 4-10 µg/mL against a chloroquine-resistant strain. This is laboratory test-tube data, not animal or human evidence.
Critically, in vitro activity does not translate to clinical efficacy. Hundreds of plant compounds kill parasites in cell culture but fail to demonstrate benefit in living organisms due to bioavailability, metabolism, and other physiological barriers.
Bottom line: No human or animal evidence supports immune system benefits.
Energy & Physical Performance: Tier 1 (No Evidence)
Evidence Rating: Tier 1 — No human studies; irrelevant animal toxicology data.
Despite marketing as a performance enhancer, Fadogia agrestis has not been studied for energy, fatigue, endurance, or physical performance in any human population. The only available PubMed abstract is a toxicology study in rats showing cellular damage to liver and kidney tissue—research entirely irrelevant to energy claims.
No energy production, metabolic markers, exercise capacity, or fatigue measures have ever been assessed with this supplement.
Heart Health: Tier 1 (No Evidence; Concerning Animal Data)
Evidence Rating: Tier 1 — No cardiovascular studies; adverse reproductive effects in animals.
No evidence supports Fadogia agrestis for cardiovascular health. The single animal study examining testicular function in rats found adverse effects on reproductive markers with no assessment of heart health parameters whatsoever. This supplement should not be promoted for cardiac or vascular benefits.
Liver Health: Tier 1 (Evidence of Harm, Not Benefit)
Evidence Rating: Tier 1 — Evidence of hepatotoxicity, not liver support.
Rather than supporting liver health, Fadogia agrestis demonstrates evidence of hepatotoxic effects in animal research. In a rat study, Fadogia agrestis extract at doses of 18-100 mg/kg significantly reduced liver enzyme activity, including alkaline phosphatase, lactate dehydrogenase (LDH), and gamma-glutamyl transferase (GGT), while corresponding serum concentrations of these enzymes increased (p<0.05). This pattern indicates hepatocyte damage and leakage of intracellular enzymes.
Additionally, serum malondialdehyde—a marker of lipid peroxidation and oxidative stress—increased significantly across all extract-treated rat groups, indicating hepatic oxidative stress and cellular membrane damage.
Bottom line: This supplement should not be used for liver support and may pose hepatotoxicity risk with sustained use.